Study of the Efficacy, Safety and Immunogenicity of OncoVEXGM-CSF in Patients with Stage IIIc and Stage IV Malignant Melanoma

Sponsor ID

002-03

Clinicaltrials.gov ID

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

Phase

Phase 2

Product

talimogene laherparepvec (T-VEC)

Type

Interventional

Masking

N/A

Enrollment

N/A

Additional Study Details

Primary Outcome Measures

Not Available

Secondary Outcome Measures

Not Available

Study Synopsis

Available Language(s): English

No locations found.